|
1）Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998; 287: 860-7
|
|
|
|
2）Ross EA. Congestive renal failure: the pathophysiology and treatment of renal venous hypertension. J Card Fail. 2012; 18: 930-8
|
|
|
|
|
3）Matsuzaki M, Hori M, Izumi T, et al; Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011; 25 Suppl 1: S33-45
|
|
|
|
|
|
4）Schrier RW. Use of diuretics in heart failure and cirrhosis. Semin Nephrol. 2011; 31: 503-12
|
|
|
|
|
|
5）Cowley AW Jr. Long-term control of arterial blood pressure. Physiol Rev. 1992; 72: 231-300
|
|
|
|
|
|
6）Cowley AW Jr, Mori T, Mattson D, et al. Role of renal NO production in the regulation of medullary blood flow. Am J Physiol Regul Integr Comp Physiol. 2003; 284: R1355-69
|
|
|
|
|
|
7）Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009; 53: 589-96
|
|
|
|
|
|
8）Romero JC, Knox FG. Mechanisms underlying pressure-related natriuresis: the role of the renin-angiotensin and prostaglandin systems. State of the art lecture. Hypertension. 1988; 11(6 Pt 2): 724-38
|
|
|
|
|
|
9）Sawyer WH, Manning M. The use of antagonists of vasopressin in studies of its physiological functions. Fed Proc. 1985; 44(1 Pt 1): 78-80
|
|
|
|
|
|
10）Yamamura Y, Ogawa H, Yamashita H et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992; 105: 787-91
|
|
|
|
|
|
11）Mori T, Oba I, Koizumi K, et al. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis. Adv Perit Dial. 2013; 29: 33-7
|
|
|
|
|
|
12）Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006; 290: F273-8
|
|
|
|
|
|
13）Morooka H, Iwanaga Y, Tamaki Y, et al. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ Heart Fail. 2012; 5: 484-92
|
|
|
|
|